Programme Thesis
The Innovate UK Biomedical Catalyst Accelerator – Future Medicines is a grant and support programme designed to help UK-based SMEs, spinouts, and academic entrepreneurs develop and commercialise next-generation therapeutics, diagnostics, and digital health solutions. It exists to accelerate innovation in areas like radiopharmaceuticals, gene therapies, and antimicrobial resistance by providing tailored technical, commercial, and investment-readiness support, culminating in a grant application draft.
Selection Criteria
- UK-based SME, spinout, or academic in early stages of forming an SME
- Technology at TRL 2-4 (early-stage, proof-of-concept to lab validation)
- Clear commercial route to market
- Innovation within scope: radiopharmaceuticals, microbiome/phage therapies, biopharmaceuticals, regenerative/personalised medicines, gene/CAR-T therapies, antimicrobial resistance
- Demonstrated healthcare challenge addressed
- Particularly encouraged: radiopharmaceuticals innovation
- Pre-Accelerator (Nov-Dec 2025) open to all eligible; Accelerator (Jan-Mar 2026) selects a subset based on potential
Past Winners / Cohort Profiles
No specific past winners listed on the page. Typical archetypes: early-stage UK biotech spinouts developing novel therapeutics (e.g., radiopharmaceuticals, gene therapies), academic founders with a patent or prototype, SMEs with a digital health platform for drug development. Cohorts are small and highly curated, with emphasis on commercial viability and technical novelty.
Ideal Candidate Fingerprint
A UK-based early-stage SME or academic spinout with a novel therapeutic or platform technology at TRL 2-4, addressing a clear unmet healthcare need in future medicines (e.g., radiopharmaceuticals, AMR). The ideal applicant has a strong scientific foundation, a credible commercialisation plan, and is ready to engage with expert mentors to refine their R&D and funding strategy.
Recommended Framing
Eniola should position his TOPOLOGIX platform (ESM-2 + ML for drug-resistance mutation prediction) as a digital health tool addressing antimicrobial resistance (AMR), a priority area for this accelerator. He can frame it as a software-as-a-service (SaaS) for pharma R&D, with a clear commercial route (licensing to biotech/pharma) and early-stage TRL (3-4). His independent researcher status and Nigerian background could be leveraged to highlight global health impact, but he must address the UK-based SME requirement—potentially by partnering with a UK academic or forming a UK-registered company.
Watch Out
Applicant is not UK-based (Nigerian, enrolled in German MSc) and is an independent researcher, not an SME or academic spinout. The programme explicitly requires UK-based SMEs or academics forming an SME. Eniola would need to establish a UK entity or collaborate with a UK-based partner to be eligible. No mention of funding amount or deadline on the page.